These included 186,144 people with epilepsy, 169,127 with peripheral neuropathy (PN), 60,861 with Alzheimer ... the ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on ...

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

(SPONSORED) — Dr. Joshua Logan, DC, BCN, founder of True North Health Center, is board-certified in neuropathy and has been awarded “Best Holistic Pain Management” in Colorado Springs.

[16] The reported incidence in the earlier literature varies from no neuropathy to over 90%. [1],4-8,20] This might be due to differences in patient selection or variation in the criteria used for ...

Patients with Huntington’s disease have a genetic mutation that triggers proteins to misfold and clump together in the brain.

(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...

23, 2024 — Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar ... Oct. 18, 2024 — A new article ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.